Summary: Depression is a highly prevalent and disabling condition associated with significant morbidity and mortality. Currently available treatments for depression include tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, various atypical antidepressants, and electroconvulsive therapy. Although these treatments are effective, a significant number of patients do not respond or achieve sustained remission despite aggressive management. Advances in the neurobiology of depression have suggested a number of novel targets for antidepressant treatment. Based on an improved understanding of the neurobiology of depression, several novel pharmacologic and nonpharmacologic interventions are being developed. Pharmacologic developments include CRF antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA glutamate receptor antagonists, transdermal selegiline, so-called "triple" reuptake inhibitors, and augmentation of typical antidepressant medications with atypical antipsychotics. Nonpharmacologic advances have largely involved focal brain stimulation techniques including vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation. For the most part, the data on these treatments are preliminary, and more study is needed to clarify their potential clinical benefit. However, it is clear that further study of the neurobiology of depression will continue to provide a rationale for developing innovative targets for antidepressant therapies.
INTRODUCTION
Depression is one of the most common neuropsychiatric conditions, with a lifetime prevalence approaching 17%. 1 Depression also ranks as one of the most significant causes of disability worldwide, second only to ischemic heart disease. 2 Fortunately, depression is highly treatable. Pharmacotherapy, certain forms of psychotherapy and electroconvulsive therapy (ECT) have all shown antidepressant efficacy and can significantly improve quality of life of patients. Unfortunately, despite clear benefits for these treatments, many problems and unanswered questions remain.
Although medications, psychotherapy, and ECT can all be effective in treating depression, a significant number of patients do not respond fully to available treatments. Almost half of depressed patients continue to have some residual depressive symptoms despite adequate treatment, 3 and up to 20% may show minimal or no response to even the most aggressive interventions. 4 -6 Other patients are unable to tolerate currently available treatments. For patients who can tolerate and eventually respond to current treatments, time to response may take several weeks, and relapse is common. Long-term prophylactic treatment is often required to limit number and severity of depressive episodes over time. Research into the neurobiological underpinnings of mood disorders has progressed rapidly over the last several decades, and major strides have been made in understanding the neurochemical, neuroanatomical, and genetic bases for depression and related disorders. This work has served to suggest promising new directions for antidepressant treatment development.
In this review, we highlight developing treatments for depression based on an expanding neurobiological understanding of mood disorders. We first discuss current evidence-based treatments for depression including medications that modulate monoaminergic neurotransmission and electroconvulsive therapy. [Although a growing database supports a neurobiological basis for the efficacy of certain psychotherapies (such as cognitive behavioral therapy), 7, 8 a review of this literature is beyond the scope of this article.] Next, we review several promising new treatments that will be presented in two groups: pharmacologic interventions and brain stimulation techniques. This review will show how continued study of the biology of depression holds great promise for providing the rationale for the development of novel treatment strategies.
ESTABLISHED SOMATIC TREATMENTS FOR DEPRESSION

Modulation of monoaminergic neurotransmission
A myriad of controlled trials have established the antidepressant efficacy of medications that modulate monoaminergic neurotransmission (Table 1) , primarily the serotonin and norepinephrine systems. These medications typically act by inhibiting reuptake of norepinephrine and/or serotonin from the synapse, inhibiting monoamine oxidase (which degrades these neurotransmitters) or acting at receptors that modulate monoaminergic transmission. Monoaminergic modulators generally include the tricyclic and tetracyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs) and various "atypical" antidepressants with less well-described mechanisms of action.
TCAs are among the oldest antidepressant medications available and were, for many years, the pharmacologic treatment of choice for depression. A substantial literature demonstrates antidepressant efficacy for these medications. 9, 10 As a class, these agents are potent inhibitors of norepinephrine and/or serotonin reuptake into the presynaptic terminal. These medications also tend to block muscarinic cholinergic receptors and, as a result, are associated with anticholinergic side effects including dry mouth, dry eyes, constipation, blurred vision, urinary hesitancy, mild cognitive disturbance, and tachycardia. They also have antihistamine effects resulting in sedation and weight gain. Because of these side effects (and the considerable cardiac toxicity observed after TCA overdose), the TCAs have largely been replaced by other antidepressants as first-line agents in the treatment of depression.
Irreversible nonselective MAOIs are also among the oldest available antidepressant medications. The MAOIs prevent the degradation of all monoamines within the presynaptic terminal. These agents are clearly efficacious in depression. 11 Importantly, MAOIs have also been shown to be especially effective in the treatment of "atypical" depression which accounts for 15-20% of major depression; atypical depressive episodes are characterized by substantial mood reactivity and "reverse" neurovegetative symptoms (increased sleep, increased appetite). These medications are limited by two to three times per day dosing, a less-than-favorable side effect profile and the tyramine-free diet required with their use. As well, MAOIs can interact with other agents that affect the monoaminergic systems to produce synergistic-and dangerous-effects. Table 1 lists MAOIs available in the U.S.
Because of their relatively benign side effect profile and limited drug-drug interactions, the SSRIs have largely replaced the TCAs and MAOIs as first-line agents in the treatment of depression. 12 SSRIs strongly and selectively inhibit the reuptake of serotonin into the presynaptic terminal. As a class, they have little effect on norepinephrine reuptake and little to no effect on cholinergic or histaminergic function. However, their robust proserotonergic activity results in several, relatively unique, side effects including gastrointestinal distress (nausea, diarrhea, constipation), insomnia, nervousness and agitation, and sexual dysfunction. Although these side effects are often tolerable and/or time-limited in most patients, they lead to discontinuation in a substantial minority of treated subjects. Numerous randomized controlled trials have demonstrated the efficacy of these agents for depression and several anxiety disorders. 12 Serotonin/norepinephrine reuptake inhibitors were designed to provide the pharmacological benefit of dual reuptake blockade exemplified by certain TCAs without their characteristic side effects. Currently, only two SNRIs, venlafaxine and duloxetine, are clinically available in the U.S., although a third, milnacipran, is avail- 13 and certain anxiety disorders, such as generalized anxiety disorder. 14, 15 In its immediate release form, the side effects of venlafaxine (mostly similar to SSRIs) can occasionally be severe and limit its tolerability. 16 An extended release version is much better tolerated, although still associated with occasional side effects, including exacerbation of hypertension, and the question of overdose death liability and adverse effects on the heart remain unresolved. [17] [18] [19] [20] Duloxetine is the newest SNRI available, and as such its tolerability and efficacy in clinical populations is less well described. However, current data indicate that it is indeed an effective antidepressant medication with good tolerability, even in "sensitive" groups such as the elderly. 21, 22 "Atypical" antidepressants (bupropion, mirtazapine, nefazodone, and trazodone) are also widely used in the treatment of depression. In general, the mechanisms of action for these medications are poorly understood but still suggest modulation of monoaminergic systems. Bupropion has been available for many years and appears to be relatively weak in its effects on serotonin, norepinephrine or dopamine transporters. However, its efficacy is well documented and equal to that of SSRIs, and its side effects are limited. 23 The most significant side effect related to immediate-release bupropion is a slightly decreased seizure threshold such that use in populations with higher risk for seizure is contraindicated; there are, however, data suggesting that slower release forms of the medication may be less likely to cause seizures. In addition, there is some evidence that bupropion may counteract the sexual side effects of SSRIs when used in combination. 24 Mirtazapine, which may act at several pre-and postsynaptic serotonin and ␣ 2 adrenergic receptors, is efficacious in treating depression and is relatively well tolerated. 25 Its most significant side effects are sedation and weight gain, which decrease in severity with increasing doses. Nefazodone is a potent blocker of 5-HT 2 serotonin receptors and a weak inhibitor of serotonin and norepinephrine reuptake. 26, 27 This agent is an effective antidepressant and has shown efficacy in treating chronic depression. 28 Unfortunately, nefazodone is rarely associated with lethal hepatitis, and its clinical use is now limited. 29 Trazodone, which is structurally similar to nefazodone, is also efficacious in the treatment of depression, although its major side effect of sedation limits its use. This agent is still frequently used as a sedative-hypnotic, although the data supporting this use are limited.
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Electroconvulsive therapy
Electroconvulsive therapy (ECT; Table 1 ) is generally considered to be the most efficacious acute treatment for depression 31, 32 and has the longest history of continued use of all available treatments. With ECT, an electric current is generated in the brain using electrodes placed on the scalp, and this current induces a generalized seizure. Although this aspect of the treatment has remained unchanged since its introduction, advances in anesthesiology have greatly improved the safety and tolerability of ECT. Response rates with ECT, even in treatmentresistant patients, can be as high as 50 -90%.
33-36 ECT reduces suicide attempt rates and has been shown to reduce overall mortality rates in depressed patients over 3 years of follow-up. 33, 37 Despite its potential benefits, ECT still has significant risks and side effects including post-ictal confusion, transient memory disturbance, and cardiopulmonary complications. 5, 38, 39 Bitemporal ECT remains the gold-standard for ECT in terms of efficacy-no other antidepressant treatment or ECT electrode placement has shown superiority to bitemporal ECT in the treatment of depression. However, bitemporal ECT is also associated with significant cognitive side effects including retrograde and anterograde amnesia and confusion. 40, 41 Other electrode placements have attempted to decrease the side effects of ECT without compromising efficacy. Both right unilateral and bifrontal lead placements have shown efficacy in treating depression with fewer cognitive side effects than bitemporal ECT. 41, 42 Despite this, the side effects of ECT still limit its use. Also, although ECT is effective as an acute treatment, it is associated with a high relapse rate, with some investigators claiming a 4% per day worsening of depression symptom severity after completion of a treatment regimen. 43 The mechanism of action of ECT is unknown, although data suggest that ECT may act through effects on monoaminergic systems (including dopamine, serotonin, and down-regulation of ␤ adrenergic receptors), by reducing corticotropin-releasing factor (CRF) availability, 44 or by effects on other neurotrophic factors and neuroendocrine systems (for review see Wahlund and von Rosen). 45 ECT also has anticonvulsant effects that have been related to its efficacy.
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ADVANCES IN THE TREATMENT OF DEPRESSION
Pharmacological interventions
Modulators of CRF and glucocorticoids. Psychological and physiological stress is known to precipitate depression in vulnerable individuals. In mammals, the stress response is largely coordinated by CRF, the neuropeptide that controls the hypothalamic-pituitary-adrenal (HPA) axis. Neurons in the paraventricular nucleus of the hypothalamus release CRF into the hypothalamohypophysial portal system. CRF then stimulates adrenocorticotropin (ACTH) release from the anterior pituitary into the systemic circulation which in turn stimulates the adrenal cortex to secrete glucocorticocoids. Outside of the HPA axis, however, CRF and CRF receptors have a widespread but heterogeneous distribution, including cortical, subcortical and brainstem regions. Importantly, CRF has been found to modulate not only the endocrine stress response but also autonomic, immunologic, and behavioral responses as well. 47 The HPA axis exhibits hyperactivity in patients with depression and considerable evidence suggests that this is driven by increased activity of CRF pathways.
48 Patients with depression exhibit a substantial elevation of CSF CRF concentrations compared with controls, and there is increased CRF mRNA expression and an increase in the number of CRF-containing neurons in the paraventricular nucleus of depressed patients versus controls. 48 Further support for a role for CRF in the pathophysiology of depression is provided by data that antidepressants modify CRF activity. In a group of healthy volunteers, desipramine was shown to decrease CSF CRF concentrations. 49 Fluoxetine and ECT have been reported to produce similar changes in depressed patients. 44 Taken together, these data support a potential role in treating depression for agents that directly reduce CRF activity and function.
Two main receptor subtypes for CRF have been identified. CRF 1 receptors strongly bind CRF, are widely distributed throughout the brain, and decreased activity of these receptors has been linked with less anxiety in animal models.
47 CRF 2 receptors bind CRF less strongly than CRF 1 receptors, have a widespread distribution that appears to have limited overlap with that of CRF 1 receptors, and decreased activity has been linked with increased anxiety-like behaviors. 47 Although most work to date has been devoted to developing selective CRF 1 receptor antagonists as putative antidepressant/anxiolytics therapies, CRF 2 agonists might offer an additional, useful target for novel treatments.
Several CRF 1 antagonists have been developed, and they exhibit anxiolytic and antidepressant activity in animal models (Table 2 ; see Gutman et al. 47 for a review). To date, only one agent (R121919) has published data on 50 This agent showed evidence of antidepressant activity 50 but is no longer a viable drug candidate due to liver toxicity. However, these data do demonstrate important "proof of principle" for CRF 1 receptor antagonists, an impetus to further studies of these agents.
Another neuroendocrine target for novel drug development is glucocorticoid synthesis inhibitors and glucocorticoid receptor blockade. The data are limited on agents that interfere with cortisol synthesis (such as ketaconozale, aminogluthemide, and metyrapone) but do suggest potential antidepressant effects; however, these agents are also associated with a number of unfavorable side effects. 51 The best studied glucocorticoid receptor antagonist in depression is mifepristone (RU486; Table  2 ), which is a selective type II glucocorticoid receptor blocker. An early open study of mifepristone suggested antidepressant effects in four patients with severe, chronic depression. 52 More recent studies have focused on the treatment of psychotic depression which is characteristically associated with hypercholesterolemia. 53 A small crossover, placebo-controlled study and a larger open-label study showed notable antidepressant and antipsychotic effects for mifepristone 54, 55 ; the open-label study showed that a higher dose of mifepristone (600 or 1200 mg) was more effective than low dose (50 mg). 55 Also, beneficial effects were seen within 7 days. In general, the most robust effects observed were on the psychotic symptoms as opposed to the core depressive symptoms. These data support the conduct of large, double-blind, placebo-controlled trials which are underway.
In summary, the role of the neuroendocrine stress response system in the pathophysiology of depression appears to be preeminent, and a number of novel antidepressant drugs that target this system have been identified. Although results to date are limited, this exciting direction for research holds promise, and a number of definitive clinical trials are underway.
Substance P antagonists. Neurokinins are a family of neuropeptides widely distributed in the CNS and the periphery that have been implicated in pain neurotransmission. Substance P (NK-1) is the most abundant and well studied of the mammalian neurokinins. Substance P is found in neurons in the amygdala, hypothalamus, periaqueductal gray matter, locus ceruleus, and parabrachial nucleus, 56 and is colocalized in certain serotonin-and norepinephrine-containing cell bodies.
57-60 Substance P binds to several neurokinin receptor subtypes (NK-1, NK-2, NK-3, NKA, NKB). Administration of substance P to animals can elicit a behavioral and physiologic stress response and a "defense reaction." 61, 62 Conversely, the behavioral and physiologic response to stress can be attenuated by substance P antagonists.
63,64 CSF substance P levels are elevated in patients with depression, [65] [66] [67] and decreased substance P levels have been reported to be associated with better response to antidepressants. 66 In an initial placebo-controlled study of a substance P NK-1 receptor antagonist (MK-869), antidepressant effects were demonstrated. 63 However, subsequent doubleblind placebo-controlled studies revealed no antidepressant efficacy of this compound. 68 These discouraging results are difficult to reconcile. Another selective NK-1 receptor antagonists (L-759274) showed modest but statistically significant antidepressant effects in a placebocontrolled trial, 69 and another agent (CP-122721) has shown clinical evidence of antidepressant effects. 70 Generally, these drugs (Table 2 ) appear to be well tolerated.
NMDA glutamate receptor antagonists. Glutamate is recognized as the primary excitatory neurotransmitter in the brain. Glutamate receptors are divided into two types: ionotropic (including the NMDA, AMPA, and kainite receptors) and metabotropic (including a family of g-protein coupled receptors associated with adenyl cyclase and phosphoinositide second messenger systems). A growing database supports a role for excitatory glutamatergic neurotransmission in the pathophysiology of depression. 71, 72 As above, stress has been linked with depression, and it has been proposed that stress may contribute to depression by causing excitatory (primarily glutamatergic) neurotoxicity for cells in brain regions involved in mood regulation. Ionotropic glutamate receptor antagonists have been shown to decrease stress-induced atrophy in hippocampal neurons. 73, 74 Data also suggest amantadine (a nonselective NMDA receptor antagonist) may enhance antidepressant-like effects of typical antidepressants in animal models. 75, 76 Preclinical studies have shown that selective NMDA receptor antagonists have antidepressant-like effects in animal behavioral models (Table 2) 77,78 and that AMPA receptor potentiators may augment typical antidepressant effects. 79 Riluzole, which inhibits glutamate release, may have antidepressant effects in patients with bipolar depression 80, 81 ; however, this agent has not been tested in placebo-controlled trials or in patients with unipolar depression. Amantadine has shown very preliminary potential as an augmentation agent in treatment-resistant depression. 82 Further clinical studies of other glutamatemodulating agents in depression appear warranted.
Transdermal selegiline. As above, MAOIs have clearly documented efficacy in depression, but their use is limited by dosing, side effects and the required tyramine-free diet. The majority of clinically available MAOIs are nonselective, irreversible inhibitors of both isozymes of monoamine oxidase (monoamine oxidases A and B). Oral selegiline (which is a selective, irreversible MAO-B inhibitor at lower doses, but nonselective at higher doses) has shown antidepressant efficacy in prior studies-but only at doses where it shows nonselective MAOI activity (supporting a role for either both MAO isozymes or MAO-A in the pathophysiology of depression). 83 Given that the dietary restrictions required with use of a nonselective MAOI are largely related to inhibition of mucosal MAO isozymes, a transdermal delivery system for selegiline was developed to allow selective targeting of brain MAOs. 84 This treatment has shown antidepressant efficacy in three placebo-controlled trials 85, 86 (data on file, Somerset Pharmaceuticals, Tampa, FL), though two other placebo-controlled trials have shown no benefit 86 (data on file, Somerset Pharmaceuticals) ( Table 2) .
Triple reuptake inhibitors. As discussed above, most currently available antidepressant medications affect serotonin and/or norepinephrine activity (principally through blocking reuptake at the presynaptic terminal). However, it is highly probable that dopamine also plays a role in the pathophysiology of depression. [87] [88] [89] [90] Thus, interest has focused on developing antidepressant medications that effectively inhibit reuptake of dopamine in addition to serotonin and norepinephrine-such agents are referred to as "triple reuptake inhibitors." Two triple reuptake inhibitors (DOV 21,947 and DOV 216,303) ( Table 2 ) have shown preclinical evidence for antidepressant like effects 91, 92 ; one follow-up study has shown that DOV 216,303 is safe and tolerable in humans. 93 Further study of these agents is warranted.
Augmentation with atypical antipsychotics. Pharmacologic augmentation is common in the treatment of depression. 94 Previous augmentation strategies have most often involved the combination of SSRIs with bupropion, 95 addition of lithium, 96 or addition of thyroid hormone. 97 A novel augmentation strategy involves the use of atypical antipsychotics. Atypical antipsychotics were originally designed to treat schizophrenia with equal efficacy but fewer extrapyramidal side effects compared with typical antipsychotics (such as haloperidol and perphenazine). 98 In the U.S., the currently available atypical antipsychotics are clozapine, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. These agents generally show weak blockade of the dopamine 2 (D2) receptor and increased activity at serotonin and possibly glutamate receptors 99 ; aripiprazole differs in that it functions as a partial agonist at the D2 receptor. These agents indeed have fewer extrapyramidal side effects compared with traditional antipsychotics and are associated with a much lower rate of tardive dyskinesia. 98 However, drugs in this class have been associated with a unique and challenging set of side effects including weight gain, glucose intolerance, and serum lipid abnormalities. 100 Since their introduction, the atypical antipsychotics have demonstrated efficacy in treating schizophrenia, 101 as well as bipolar disorder (including manic, mixed, depressed, and maintenance phases of the illness). 102 Specific drugs in this class have also been found to augment SSRI action in certain anxiety disorders, including obsessive-compulsive disorder (OCD) [103] [104] [105] and post-traumatic stress disorder (PTSD). 106 -108 Several reports suggest the atypical antipsychotics may also augment standard antidepressant medications, even in the absence of psychotic features in the depressive episode (Table 2) .
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Focal brain stimulation
Neuroanatomical models of depression suggest dysfunction within a frontal cortical-subcortical-brainstem neural network in depressed patients. 114 -116 These models suggest that selective modulation of specific brain regions within this network could be beneficial in the treatment of depression. Most current treatments for depression (medications and ECT) do not act specifically at discrete brain regions. Surgical interventions for refractory depression do target specific brain regions [117] [118] [119] [120] but result in permanent lesions that cannot be adjusted or reversed. As a result, much interest has recently focused on focal brain stimulation therapies for depression (Table 3) .
Vagus nerve stimulation
Vagus nerve stimulation (VNS) is accomplished through a surgical procedure that connects an electrical stimulator to a patient's left vagus nerve. This stimulator is then attached to a programmable pulse generator that is surgically implanted subcutaneously in the patient's 121 Surgical complications are rare, with incision pain being the most commonly reported adverse event. Common side effects of treatment include voice hoarseness and coughing. In general, VNS appears to be well tolerated and acceptable to patients. VNS was originally approved by the Food and Drug Administration for treatment-resistant epilepsy 122 and was recently approved for the adjunctive treatment of a major depressive episode that has not responded to at least four antidepressant medication trials.
The initial rationale for VNS in the treatment of depression was based on mood improvements reported by epileptic patients receiving VNS, 123 and evidence that the antidepressant effects of ECT may be associated with its anticonvulsant effects. 124 One open study and one double-blind study have shown antidepressant efficacy for VNS in epilepsy patients with comorbid depression. 125, 126 A single open study of VNS in 60 nonepileptic patients with treatment-resistant depression found a 31% response rate and 15% remission rate after 10 weeks. 127 These response and remission rates were sustained at 1 year 128 and improved at 2 years after surgery. 129 Based on these data, a large, sham-controlled study was conducted but failed to show statistically significant antidepressant effects for active VNS 130 ; at the end of the initial 10-week evaluation period, response rate was 15% with VNS and 10% with sham. When all patients then received open, active VNS for up to 1 year, the response rate increased to 27% and remission rate was 16%. 131 These 1-year response and remission rates compared favorably to those of a medication management, observation-only comparison group of similarly treatment-resistant patients (13% response and 7% remission in the observation-only group). 132 Longer term response, remission, and relapse data are not currently available for this group of patients.
The potential mechanisms of action of VNS in epilepsy and depression are currently unknown. However, the central projections of the vagus nerve via the nucleus tractus solitarius innervate multiple brain areas implicated in mood regulation, and functional brain imaging studies have confirmed that VNS alters activity of many of these cortical and subcortical regions. 133 VNS may affect function of the GABA, 134 ,135 dopamine 136 and especially norepinephrine [137] [138] [139] [140] systems, although these data are not unequivocal. 136 Importantly, effects on these neurotransmitter systems, when present, have not consistently been associated with therapeutic response. 134 In summary, VNS is a relatively safe, well-tolerated treatment that may have efficacy when used chronically in patients with treatment-resistant depression. Current efficacy data are mixed, with a large, sham-controlled study finding no statistically significant acute antidepressant effects. However, long-term follow-up data suggest response and remission may increase over time in VNStreated patients, and that 1-year response and remission rates may be statistically and perhaps clinically better than results achieved with "treatment-as-usual." However, no randomized, controlled data are yet available to support this conclusion. The long-term effects of VNS in treatment-resistant depression are unknown, and it is not yet clear which patients may be more or less likely to benefit from this treatment. Further study is clearly warranted given that even a small percentage of responders in this extremely treatment refractory patient population would be an important advance in the field.
Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) uses a current passed through an electromagnetic coil on the scalp to create a brief, rapidly changing magnetic field. This magnetic field experiences little to no impedance from the scalp, skull and air, and is able to induce a small, focal electrical current within the underlying cortex, resulting in depolarization of cortical neurons. Whereas single-pulse TMS is an established diagnostic and research tool in humans, 141 repetitive TMS (rTMS) has been most extensively studied as a possible treatment for depression. rTMS delivers several discrete electrical pulses to the cortex in a short period of time. This group of pulses is referred to as a "train" of stimuli and, typically, several trains of rTMS are delivered within a single session. By convention, high-frequency or "fast" rTMS refers to stimulation delivered at a rate higher than 1 Hz, and low-frequency or "slow" rTMS refers to stimulation at frequencies of 1 Hz or slower. Fast rTMS applied to the motor cortex is associated with an increase in motor cortical excitability that persists beyond the end of stimulation, 142 whereas slow rTMS is associated with a decrease in motor cortical excitability. 143 TMS is typically "dosed" by reference to the patient's motor threshold (MT). The MT is defined as the intensity of single pulse TMS required to generate a motor response in one of the small hand muscles (often the abductor pollicis brevis or first dorsal interosseous) during half of a series of trials. No anesthesia is needed when giving rTMS (except in the case of magnetic seizure therapy (MST) discussed separately below). Although approved for the treatment of depression in Canada and other countries, in the U.S. rTMS is only available in clinical research trials.
The rationale for rTMS as a treatment for depression was initially based on a converging database implicating prefrontal cortical dysfunction in depression and showing focal neuromodulatory and behavioral effects of rTMS in animals and humans. Both neuroimaging and human stroke data have strongly supported a role for the dorsolateral prefrontal cortices (DLPFC) in depression, with both data sets suggesting that depression is associated with decreased activity of the left DLPFC. 144 -146 Combined with the excitatory effects of high-frequency rTMS over the motor cortex, it was suggested that rTMS might be used to increase function in this apparently hypoactive brain region in patients with depression. 147 Such intervention was supported in principle by data on TMS in healthy subjects showing acute mood changes with stimulation of the dorsolateral prefrontal corticesalthough the direction of change was not consistent with the expected mood effects in depressed patients. 148 Furthermore, rTMS showed behavioral changes in animals similar to those achieved with electroconvulsive shock and suggestive of an antidepressant effect. 149 Several early, small open and controlled studies showed mild to moderate antidepressant effects with fast rTMS applied to the left DLPFC; see Burt et al. 150 for a review. Some studies suggested potentially marked and rapid effects in patients with treatment-resistant depression. For example, Epstein et al. 151 found a 56% response rate in 32 medication-resistant patients treated with five sessions of 10 Hz, left DLPFC rTMS at 110% MT intensity. These encouraging results led to the conduct of several, slightly larger sham-controlled studies. Based on these studies, a number of meta-analyses, each using slightly different inclusion/exclusion criteria and statistical methods, have agreed that high-frequency (Ն5 Hz), left DLPFC rTMS given for at least 10 daily sessions results in statistically significant antidepressant effects. 150, [152] [153] [154] However, the response rates with rTMS have not consistently matched those seen in earlier open trials; Holtzheimer et al. 152 for example, found the average response rate (defined as a decrease of 50% or more in depression ratings) across all studies using high-frequency, left DLPFC rTMS was 18% for active rTMS and 2% for sham rTMS. It therefore remains unclear whether antidepressant effects of rTMS, even if statistically significant, are clinically meaningful. 155 A number of factors should be considered in interpreting the available rTMS data. First, it should be noted that the difference between active and sham rTMS response and remission rates is on the order of that seen in metaanalyses of antidepressant medication trials. 13, 156 Second, nearly every prior rTMS treatment study has exclusively included patients with treatment-resistant depression. Having failed at least one adequate antidepressant medication trial has been shown to significantly reduce the likelihood of responding to other treatments, including ECT. 3, 36 Third, other patient factors may affect likelihood of response to rTMS. Pooled data suggest that presence of psychosis and older age are associated with a lower response rate with rTMS 157 ; as well, shorter duration of current episode may predict response to rTMS. 158 Fourth, it is unlikely that the rTMS studies to date have used optimized antidepressant treatment parameters. Increased stimulation intensity, more daily treatment sessions, and greater overall number of rTMS pulses delivered are likely related to greater antidepressant efficacy. 157 A recently completed sham-controlled study of rTMS used 15 sessions of 10 Hz, 110% MT, left DLPFC rTMS in 68 patients with treatment-resistant depression and found a response rate of 31% for active rTMS compared with 6% for sham rTMS; remission rates were 20% for active rTMS and 3% for sham rTMS. 159 Additional evidence for the clinical efficacy of fast rTMS to the left DLPFC comes from several favorable comparisons with ECT. 160 -163 Although one of these studies showed ECT to be superior to rTMS in treating patients with psychotic depression, 160 these studies showed no statistically significant difference in antidepressant response between rTMS and ECT in nonpsychotic depressed patients. All studies used more than 10 treatment sessions and stimulated at 100% MT or greater. Importantly, these studies were not powered to demonstrate statistical equivalence between the two treatments, did not include a sham rTMS comparison, and did not consistently use the most aggressive ECT parameters. However, they still suggest that rTMS may possess antidepressant effects similar to ECT in some patients.
Other forms of rTMS have also shown evidence of antidepressant efficacy. Slow rTMS applied to the right DLPFC had antidepressant effects in several open 164 -167 and controlled studies. [167] [168] [169] Low-frequency, left DLPFC rTMS has shown efficacy in a few small controlled studies. 170 -172 Other investigators have explored combinations of various rTMS parameters with mixed results. [173] [174] [175] Studies of rTMS have shown it to be safe and well tolerated. 152 Despite extensive neuropsychological testing, rTMS has consistently proven to have no negative cognitive side effects. 176, 177 Transient auditory threshold increases have been reported with rTMS 176 ; this can be eliminated with the use of foam earplugs. Some patients report a mild headache during and/or after rTMS, but this is typically short-lived and easily treated with over-thecounter analgesics. The most concerning risk of rTMS is a generalized seizure, although this risk appears to be greatly attenuated when established safety guidelines are followed. 178 Despite its initial rationale and some preliminary supporting data, the mechanism of action of rTMS remains largely unknown. Imaging data have resulted in a mixed picture of the cortical excitatory effects of fast and slow rTMS at the prefrontal cortex, 179 -185 calling into question the "activation" of the DLPFC hypothesis for fast rTMS antidepressant effects. However, these same data also suggest rTMS can modulate the function of brain regions distant from the initial site of stimulation (DLPFC) but still implicated in the treatment of depression. Preclinical studies suggest rTMS may induce physiological and behavioral effects in animals similar to those elicited with established antidepressant treatments. 186, 187 Other data suggest frontally applied rTMS may induce dopamine release in subcortical structures 188 -193 and may alter function within other monoamine systems. 194 rTMS is therefore a potentially useful treatment for depression that requires further study to clarify the magnitude of clinical effects and its mechanism of action. It is generally safe and well tolerated and may eventually offer a noninvasive alternative to medications and other somatic treatments for depression, such as VNS and ECT. Two large, multisite studies of fast rTMS of the left DLPFC for treatment-resistant depression are currently ongoing and should produce relatively definitive results within the next 2-5 years.
Magnetic seizure therapy
MST uses a modified rTMS system to induce a generalized seizure similar to that obtained with ECT. Available data suggest that the significant cognitive side effects associated with ECT may be minimize by electrode placement selection. 41, 42 Given this, the hope with MST is that by inducing a generalized seizure with very focal electrical stimulation of the prefrontal cortex, treatment will still be efficacious (or at least as efficacious as more focal forms of ECT) with significantly fewer cognitive side effects. Although no definitive results have been reported, there is some evidence that MST results in antidepressant effects with fewer cognitive side effects than ECT. 195, 196 It remains unclear whether MST is more or less efficacious than nonconvulsive TMS.
Deep brain stimulation
With deep brain stimulation (DBS), a small electrical stimulator is implanted into a defined brain location, often a subcortical area, and connected to a programmable subcutaneous pulse generator. Bilateral DBS of the subthalamus or globus pallidus is a relatively new, but generally accepted treatment for refractory Parkinson's disease. 197 Several lines of evidence support the investigation of DBS as a treatment for depression. First, DBS has been clearly associated with significant mood changes in patients with Parkinson's disease 198, 199 ; thus, direct modulation of mood with DBS is possible. Second, functional imaging studies clearly implicate certain deep brain regions in the pathophysiology of depression, such as the amygdala and anterior cingulate cortex. 200, 201 Function in these regions could be directly modulated with DBS. Third, a small case series reported potential benefit from bilateral internal capsule DBS in patients with severe, treatment-resistant OCD. 202 One challenge in using DBS to treat depression is choosing the stimulation location. As above, internal capsule DBS may have efficacy in treating OCD, but the efficacy of this stimulation site in treating depression has not been demonstrated. The only published study of DBS in treating depression used high-frequency stimulation bilaterally in the white matter adjacent to the subgenual cingulate cortex. 203 In this study, four of six highly treatment-refractory patients (five had failed ECT) were responders at the 6-month study end-point. Three of these patients were in remission at 6 months, and one was very near remission. No significant adverse events were noted.
The mechanism of action of DBS is not known, although DBS most likely modulates function within discrete neural networks. 204 As discussed above, depression has been associated with dysfunctional frontal corticalstriato-thalamic neural circuitry. Thus, DBS may help to restore normal neural network function by activating compensatory neural pathways or possibly by circumventing dysfunctional "nodes" in the network. In the above study of DBS in the subgenual cingulate white matter, response was associated with changes in regional blood flow in brain regions clearly implicated in the pathophysiology of depression (dorsolateral prefrontal cortex, subgenual cingulate, perigenual anterior cingulate, hypothalamus, brainstem). 203 Whether these changes were achieved through inactivation of a dysfunctional node (subgenual cingulate) or activation of compensatory neural pathways is unclear.
Side effects of DBS surgery and treatment can include intracranial hemorrhage, delirium, mood changes (including depression and mania), and movement disorders. 205 It is important to recognize that these effects were observed in patients with Parkinson's disease treated with DBS. It is not yet clear what side effects may occur in non-Parkinsonian patients that undergo DBS surgery and long-term treatment-likely the potential for side effects will depend greatly on the precise stimulation site.
In summary, DBS is an innovative technique for directly altering the function of deep brain structures that has shown efficacy in treating treatment-resistant Parkinson's disease.
A very preliminary open study in refractory depression of high-frequency DBS applied to bilateral white matter adjacent to the subgenual cingulate showed promising results with no significant adverse events.
CONCLUSION
Depression is a highly prevalent and disabling condition associated with significant morbidity and mortality. Currently, available treatments for depression are effec-tive, although a significant number of patients respond poorly even to the most aggressive treatments. Advances in the neurobiology of depression have suggested a number of novel targets for antidepressant treatment. Although preliminary, results suggest that both pharmacologic innovations (CRF antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA receptor antagonists, transdermal selegiline, "triple" reuptake inhibitors and augmentation with atypical antipsychotics) and focal brain stimulation (VNS, TMS, MST, and DBS) may be effective in the treatment of depression. Although more study is needed to clarify the benefit of these treatments, it is clear that further study of the neurobiology of depression remains important as a means of providing targets for innovative targets for antidepressant therapies. 
